Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.
Clinical trial NCT02670317 · TERMINATED
Trial details
- NCT number
- NCT02670317
- Sponsor
- Fondazione Italiana Linfomi - ETS
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-01
- Primary completion
- 2017-02-01
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.